AAVHSCs. We plan to begin a Phase 1/2 clinical trial with HMI-102 in 2019, and we expect to report initial clinical data from the trial by the end of the year. HMI-102 was granted Orphan Drug Designation by the U.S. Food and Drug Administration and by the European Medicines Agency...
Announced Today Encouraging Initial Clinical Data from First Dose Level of pheEDIT Trial EvaluatingHMI-103 BEDFORD, Mass., July 27, 2023 (GLOBE NEWSWIRE) --Homology MedicinesInc. (Nasdaq: FIXX), a genetic med...
BEDFORD, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) --Homology Medicines, Inc.(Nasdaq: FIXX), a genetic medicines company, announced today the pheEDIT Phase 1 clinical trial for HMI-103, a one-time,in vivoproduct candidate that utilizes a gene editing approach for phenylketonuria (PKU...
Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare diseases by addressing the underlying cause of the disease. The Company’s clinical programs include HMI-103, a gene editing candidate for phenylketonuria (...